–News Direct–
PathAI, a global leader in AI-powered pathology, today announced a strategic partnership with Google Cloud at Bio-IT World Conference & Expo to help biopharma companies and anatomic pathology (AP) labs accelerate the adoption of AI and digital pathology.
PathAIs AISight1 Intelligent Image Management System (IMS) is an AI-native IMS that seamlessly blends PathAI and third-party algorithms into a single laboratory workflow and image analysis platform, providing researchers and pathologists direct access to powerful biomarker quantification tools that have the potential to increase lab operational efficiency and aid in disease staging and scoring. PathAI will leverage Google Clouds infrastructure to bring AISight to more biopharma companies and AP labs worldwide, enabling faster deployments of novel AI models for a variety of clinical and research needs.
"Bio-IT World is where pioneers convene to address the industry's most significant challenges, including how to leverage massive scale data from biological and clinical studies to accelerate the discovery and development of transformative new therapies for patients. PathAI partners across the drug development paradigm, firstly with biopharma by enabling the development of new insights and diagnostics and supporting global clinical trials through PathAIs AISight Clinical Trials platform, trial-ready algorithms, and Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) compliant laboratory; and also with AP labs ensuring scaled access to algorithms through AISight," said Dr. Andy Beck, CEO and co-founder of PathAI. "Our partnership with Google Cloud helps us transform our capabilities to accelerate adoption of these powerful tools and ultimately reshape how disease is understood and treated.
The partnership will involve the integration of PathAIs AISight solution with Google Cloud's infrastructure and AI capabilities, providing:
Accelerated adoption of precision medicine solutions: Google Cloud's infrastructure enables rapid scaling of AISight's digital pathology IMS and algorithmic capabilities globally, aiding digital pathology laboratory operations and researchers in processing petabytes worth of data for large-scale biomarker discovery and clinical studies, ultimately bringing advancements to patients more quickly.
Customized solutions and tailored AI models: The latest Google Cloud AI tools within the AISight platform provide the ability to quickly develop customized solutions and deploy novel AI models tailored to specific research needs.
"We understand the urgent need within the biopharmaceutical industry for secure, scalable solutions in AI-driven drug discovery, laboratory operations, and biomarker quantification, said Ryan Terry, managing director, Healthcare and Life Sciences, Google Cloud. "We're incredibly excited to partner with PathAI to create a new wave of solutions that leverage precision medicine to help solve the industrys most significant challenges."
1AISight is For Research Use Only. Not for use in diagnostic procedures.
About PathAI
PathAI is dedicated to improving patient outcomes through its groundbreaking AI-powered pathology platform. Our solutions provide invaluable insights for biopharmaceutical companies, researchers, and laboratories, ultimately enabling precision pathology and the vision of more effective treatments. Learn more at www.pathai.com.
Contact Details
SVM Public Relations and Marketing Communications
Maggie Naples
+1 401-490-9700
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/pathai-partners-with-google-cloud-to-transform-drug-discovery-and-precision-medicine-through-ai-powered-pathology-574680230
PathAI
COMTEX_450935271/2655/2024-04-16T14:48:40
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No A News Week journalist was involved in the writing and production of this article.